

Art 37

1 CLAIMS

- 2
- 3 1. Use of a test for detecting the genetic basis of
- 4 Gilbert's Syndrome in a method to improve the
- 5 efficacy of drug trials, the method comprising
- 6 screening samples from potential participants for
- 7 the basis of Gilbert's Syndrome and eliminating or
- 8 including potential participants in a drug trial
- 9 in the knowledge of them possessing or not
- 10 possessing the genetic basis of Gilbert's
- 11 Syndrome.
- 12
- 13 2. Use of a test as claimed in claim 1 wherein the
- 14 method comprise the steps of:
- 15
- 16 a) taking a sample from each potential
- 17 participant in a drug trial,
- 18
- 19 b) screening the samples for the genetic basis
- 20 of Gilbert's Syndrome,
- 21
- 22 c) identifying participants having the genetic
- 23 basis of Gilbert's Syndrome, and
- 24
- 25 d) proceeding with drugs trials in the knowledge
- 26 of participants possessing or not possessing
- 27 the genetic basis of Gilbert's Syndrome.
- 28
- 29 3 Use of a test as claimed in claim 1 or 2 wherein
- 30 the sample is chosen from blood, buccal smear or
- 31 any other sample containing DNA from the potential
- 32 participants.
- 33
- 34 4. Use of a test as claimed in any of the preceding
- 35 claims further comprising the step of eliminating
- 36 participants having the genetic basis of Gilbert's

AMENDED SHEET

Ael 36

- 1 Syndrome from a drugs trial.
- 2
- 3 5. Use of a test as claimed in any of claims 1 to 3
- 4 wherein the method comprises the further step of
- 5 selecting only participants having genetic basis
- 6 for Gilbert's Syndrome for a drugs trial.
- 7
- 8 6. Use of a test as claimed in any of claims 1 to 3
- 9 further comprising the step of interpreting the
- 10 results of the drugs trial in the knowledge that
- 11 certain participants have Gilbert's Syndrome.
- 12
- 13 7. Use of a test as claimed in any of the preceding
- 14 claims wherein the method comprises the steps of:
- 15
- 16 a) isolating DNA from each sample,
- 17
- 18 b) amplifying the DNA inner region indicating
- 19 the genetic basis for Gilbert's Syndrome,
- 20
- 21 c) isolating amplified DNA fragments, and
- 22
- 23 d) identifying individuals having the genetic
- 24 basis of Gilbert's Syndrome.
- 25
- 26 8. Use of a test as claimed in any of the preceding
- 27 claims wherein the DNA is amplified using the
- 28 polymerase chain reaction (PCR) using a
- 29 radioactively labelled pair of nucleotide primers.
- 30
- 31 ⁹ 10. Use of a test as claimed in any of claims 7 to 9
- 32 wherein the DNA region indicating the genetic
- 33 basis of Gilbert's Syndrome is the gene encoding
- 34 UDP-glucuronosyltransferase (UGT).
- 35
- 36 ¹⁰ 11. Use of a test as claimed in any of claims 7 to 10

AMENDED SHEET

Rule 126

35011 3304460

Sub
C2

D2

Apr 134

26

- 1 wherein the DNA to be amplified is in an upstream
2 promoter region of the UGT 1*1 exon 1.
3
4 11. Use of a test as claimed in any of claims 7 to 11
5 wherein the DNA to be amplified includes the
6 regions between -35 and -55 nucleotides at the 5'
7 end of UGT 1*1 exon.
8
9 12. A kit for screening individuals participation in
10 drug trials, the kit comprising primers for
11 amplifying DNA in the region of the genome
12 indicating the genetic basis of Gilbert's
13 Syndrome.
14
15 13. Primers for use of a test as claimed in any of the
16 preceding claims including primer pairs, AB or CD
17 as follows:
18
19 A/B (A, 5'-AAGTGAAGTCCCTGCTACCTT-3',
20 B, 5'-CCACTGGGATCAACAGTATCT-3') or
21 C/D (C, 5'-GTCACGTGACACAGTCAAAC-3';
22 D 5'-TTTGCTCCTGCCAGAGGTT-3').

Rule 126

SECRET

D2

Add
D3Add
F1

AMENDED SHEET